Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
Nerviano Medical Sciences will reacquire the rights to the next-gen brain penetrant PARP1 inhibitor and advance the drug into phase 1/2 trials.
read more
The FDA has approved BridgeBio’s Attruby tablets for the treatment of ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization.
read more
Sage will halt development of dalzanemdor after the drug failed to best placebo in a phase 2 study of cognitive impairment associated with Huntington’s.
read more
Endo has added more lots to its previously announced recall of Clonazepam tablets due to potential product strength mislabeling at the carton level.
read more
Linerixibat has the potential to be the first global therapy specifically developed to treat itch in primary biliary cholangitis.
read more
Azurity has won FDA approval for a re-engineered formulation of nilotinib, branded Danziten, for adults with chronic myeloid leukemia.
read more
The menin inhibitor, branded Revufori, is the first and only treatment of its kind for an aggressive form of acute leukemia.
read more
The EFSA has concluded that saccharin — once thought to cause cancer — is safe for human consumption and increased the acceptable daily intake.
read more
AbbVie announced that a pair of trials investigating emraclidine as a once-daily oral treatment for schizophrenia failed to meet their primary endpoints.
read more
Rapt is culling its clinical programs for zelnecirnon, an oral immunology drug being evaluated in asthma and atopic dermatitis.
read more
Citing efficacy data, the FDA has proposed removing the country's most popular oral nasal decongestant ingredient.
read more
Novo Nordisk will terminate the development of ocedurenone following a trial fail and $816 million loss.
read more
Viking shared promising clinical data from the company's obesity program at ObesityWeek 2024, highlighting both its tablet and subcutaneous formulations.
read more
Journey says that Emrosi could offer a new standard of care in rosacea treatment.
read more
The decision in the patent infringement lawsuit filed by Incyte will delay Sun's U.S. launch of Leqselvi.
read more